SUPPLEMENTARY TABLE

Supplementary Table S1: Summary of clinical data for 69 MPM patients

| | All | SETDB1 wild-type | SETDB1 mutant |
|-----------------------|-------|------------------|---------------|
| Number of patients | 69 | 62 | 7 |
| Mean Age | 67.2 | 67.5 | 63.7 |
| Sex, % Male | 73.9% | 75.8% | 57.1% |
| Race | | | |
| Caucasian | 83.6% | 85% | 71.4% |
| Latino | 9.0% | 6.7% | 28.6% |
| Black | 1.5% | 1.7% | 0% |
| Asian | 1.5% | 1.7% | 0% |
| Other | 4.5% | 5.0% | 0% |
| Smoking History | | | |
| Never smoker | 42.6% | 45.5% | 16.7% |
| Former smoker | 52.5% | 49.1% | 83.3% |
| Current smoker | 4.9% | 5.5% | 0% |
| Mean pack years | 29 | 30 | 24 |
| Mesothelioma Exposure | | | |
| Known exposure | 73.5% | 71.4% | 83.3% |
| Subtype | | | |
| Epithelioid | 82.6% | 82.2% | 85.7% |
| Sarcomatoid | 8.7% | 8.1% | 14.3% |
| Biphasic | 8.7% | 9.7% | 0% |
| Hemithorax | | | |
| Left | 34.4% | 30.9% | 66.7% |
| Right | 65.6% | 69.1% | 33.3% |
| Pathologic Stage | | | |
| Stage I | 45.6% | 41.2% | 83.3% |
| Stage II | 5.3% | 5.9% | 0% |
| Stage III | 43.9% | 47.1% | 16.7% |
| Stage IV | 5.3% | 5.9% | 0% |
| Overall Survival | | | |
| Mean (months) | 18.2 | 17.7 | 22.4 |
| Median (months) | 12.0 | 12.5 | 11.0 |